The role of cartilaginous glycoprotein-39 in patients with knee osteoarthritis with concomitant coronary heart disease, arterial hypertension and dyslipidemia of unclear genesis - a multidisciplinary problem
- Autores: Ktsoeva A.A.1
-
Afiliações:
- Federal State Budgetary Educational Institution of Higher Education «North Osetian state medical academy of the Ministry of Healthcare of Russia»
- Edição: Nº 3 (2018)
- Páginas: 72-77
- Seção: Articles
- URL: https://journals.eco-vector.com/2412-4036/article/view/279336
- ID: 279336
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
Objective. To study the role of cartilage glycoprotein-39 in patients with gonarthrosis in combination with cardiac ischemia, arterial hypertension and dyslipidemia, depending on inflammatory changes in joints, radiographic stage, severity of pain syndrome and degree of functional insufficiency of the joints. Material and methods. 110 patients with gonarthrosis in combination with cardiac ischemia, arterial hypertension and dyslipidemia were included in the study in the rheumatological department of NOSMA. Clinical parameters of gonarthrosis were evaluated and the concentration of cartilage glycoprotein-39, CRP, ESR and lipid spectrum was measured in serum. Results. A significant increase of cartilage glycoprotein-39 was revealed in all OA patients. The highest level of cartilage glycoprotein-39 was revealed in patients with radiographic stage III, especially if there was a reactive synovitis. There was significant correlation between the cartilage glycoprotein-39 and clinical parameters of gonarthrosis, CRP, ESR, cholesterol, CA. Conclusion. Our study of the level of cartilage glycoprotein-39, CRP, lipid spectrum indicated the presence of an inflammatory process, which is an important part of the pathogenesis of osteoarthritis and atherosclerosis.
Palavras-chave
Texto integral
Sobre autores
Alina Ktsoeva
Federal State Budgetary Educational Institution of Higher Education «North Osetian state medical academy of the Ministry of Healthcare of Russia»
Email: Kcoeva.alina.85@mail.ru
head of the receiving Department of SOGMA clinical hospital.
Bibliografia
- Алексеева Л.И., Зайцевa Е.М. Перспективные направления терапии остеоартроза // Научно-практическая ревматология. 2014;3:247-50.
- Балабанова Р.М., Эрдес Ш.Ф. Динамика распространенности ревматических заболеваний, входящих в XIII класс МКБ-10, в популяции взрослого населения Российской Федерации за 2000-2010 гг. Научно-практическая ревматология. 2012;3:10-2.
- Дубиков А.И., Кабалык М.А., Корецкая Т.Ю. Микрoкристаллический стресс в патогенезe остеоартрозa. Терапевтический архив. 2016;88(5):32-6.
- Кабалык М.А. Физические свойствa и особенности организации суставного хрящa при остеоартрозe. Дневник казанской медицинской школы. 2016;4(14):40-3.
- Кабалык М.А. Особенности ремоделирования субхондральной кости при остеоартрозe с коморбидностью. Вестник современной клинической медицины. 2016;9(4):27-32.
- Rаthcke C.N., Vestergaard H. YKL-40 - an emerging biomarker in cardiovascular disease and diabetes. Cardiovasc. Diabetol. 2009;8:61.
- Gratchev A., Schmuttermaier C., Mamidi S., Gooi L., Goerdt S., Kzhyshkowska J. Expression of osteoarthritis marker YKL-39 is stimulated by transforming growth factor beta (TGF-beta) and IL-4 in differentiating macro-phages. Biomark. Insights. 2008;3:39-44.
- Kucur M., Isman F.K., Karadag B., Vural V.A., Tavsanoglu S. Serum YKL-40 levsls in patients with coronary artery disease. Coronary Artery Dis. 2007;18(5):391-6. doi: 10.1097/MCA.0b013e328241d991
- Letuve S., Kozhich A., Аrouche N., Grandsaigne M., Reed J., Dombret M.C., Kiener P.A., Aubier M., Coyle A.J., Pretolani M. YKL-40 is elevated in patients with chronic obstructive pulmonary disease and activates alveolar macrophages. J. Immunol. 2008;181(7):5167-73. doi: 10.1371/journal.pone.0024177 Sep 11, 2014
- Hartl D., Lee C.G., Da Silva C.A., Chupp G.L., Elias J.A. Novel biomarkers in asthma: chemokines and chitinase-like proteins. Curr. Opin. Allergy Clin. Immunol. 2009;9(1):60-6.
- Thamsen S.B., Rathcke C.N., Zerahn B., Vestergaard H. Increased levels of the calcification marker matrix Gta Protein and the inflammatory markers YKL-40 and CRP in patients with type 2 diаbetes and ischemic heart diseasе. Cardiоvasc. Diabetol. 2010;9:86.
- Zheng J.L., Lu L., Hu J., Zhang R.Y., Zhang Q., Chen Q.J., Shen W.F. Increased serum YKL-40 and C-reactive protein levels are associated with angiographic lesion progression in patients with coronаry artery disease. Atherosclerosis. 2010;210(2):590-5.
- Kzhyshkowska J., Gratchev A., Goerdt S. Human chitinases and chitinase-like proteins as indicators for inflammation and cancer. Biomark. Insights. 2007;2:128-46.
- Michelsen A.E., Rаthcke C.N., Skjeltand M., Holm S., Ranheim T., Krohg-Sorensen K., Klingvall M.F., Brosstad F., Oie E., Vestergaard H., Aukrust P., Halvorsen B. Increased YKL-40 expression in patients with carotid atherosclerosis. Аtherosclerоsis. 2010;211(2):589-95.
- Johansen J.S., Schultz N.A., Jensen B.V. Plasma YKL-40: a potential new cancer biomarker? // Future. Oncol. 2009. Vol. 5. № 7. -P. 1065-1082.
- Rаthcke C.N., Raymond I., Kistorp C., Hildebrandt P., Faber J., Vestergaard H. Low grade inflammation as measured by levels of YKL-40: association with an increased overall cardiovascular mortality rate in an elderly population. Int. J. Cardiol. 2010;143(1):35-42.
Arquivos suplementares
